StreetInsider.com News Articles

BillionToOne Inc (BLLN) PT Raised to $207 at JPMorgan

Thu, 06 Aug 2026 09:15:27 -0400

JPMorgan analyst Casey Woodring raised the price target on BillionToOne Inc (NASDAQ: BLLN) to $207.00 (from $170.00) while maintaining a Overweight rating.

Form 4 BillionToOne, Inc. For: Aug 03 Filed by: Atay Oguzhan

Wed, 05 Aug 2026 20:53:00 -0400

si-local-file:///var/storage/secattach/20260805/26876597.html

Form 144 BillionToOne, Inc. Filed by: Atay Oguzhan

Wed, 05 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260805/26875544.html

Form 10-Q BillionToOne, Inc. For: Jun 30

Wed, 05 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260805/26875291.html

BillionToOne, Inc. (BLLN) Tops Q2 EPS by 12c

Wed, 05 Aug 2026 16:30:02 -0400

BillionToOne, Inc. (NASDAQ: BLLN) reported Q2 EPS of $0.15, $0.12 better than the analyst estimate of $0.03. Revenue for the quarter came in at $109.4 million.

For earnings history and earnings-related data on BillionToOne, Inc. (BLLN) click here.

Form 8-K BillionToOne, Inc. For: Aug 05

Wed, 05 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260805/26874889.html

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

Wed, 05 Aug 2026 16:05:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the second quarter ended June 30, 2026 and reiterated guidance for full year 2026.

Financial Highlights:

Total revenue of $109.4 million in the second quarter of 2026, compared to $66.6 million in the second quarter of 2025, an increase of 64%.
Prenatal clinical testing revenue was $94.2 million in the second quarter

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

Wed, 05 Aug 2026 16:05:00 -0400

Financial Highlights:

Total revenue of $109.4 million in the second quarter of 2026, compared to $66.6 million in the second quarter of 2025, an increase of 64%.
Prenatal clinical testing revenue was $94.2 million in the second quarter

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

Wed, 05 Aug 2026 16:05:00 -0400

Financial Highlights:

Total revenue of $109.4 million in the second quarter of 2026, compared to $66.6 million in the second quarter of 2025, an increase of 64%.
Prenatal clinical testing revenue was $94.2 million in the second quarter

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

Wed, 05 Aug 2026 16:05:00 -0400

Financial Highlights:

Total revenue of $109.4 million in the second quarter of 2026, compared to $66.6 million in the second quarter of 2025, an increase of 64%.
Prenatal clinical testing revenue was $94.2 million in the second quarter

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

Wed, 05 Aug 2026 16:05:00 -0400

Financial Highlights:

Total revenue of $109.4 million in the second quarter of 2026, compared to $66.6 million in the second quarter of 2025, an increase of 64%.
Prenatal clinical testing revenue was $94.2 million in the second quarter

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

Wed, 05 Aug 2026 16:05:00 -0400

Financial Highlights:

Total revenue of $109.4 million in the second quarter of 2026, compared to $66.6 million in the second quarter of 2025, an increase of 64%.
Prenatal clinical testing revenue was $94.2 million in the second quarter

Form 4 BillionToOne, Inc. For: Jul 31 Filed by: Sakakibara Shan Riku

Tue, 04 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260804/26867133.html

Form 144 BillionToOne, Inc. Filed by: Atay Oguzhan

Mon, 03 Aug 2026 12:45:00 -0400

si-local-file:///var/storage/secattach/20260803/26856361.html

Form 144 BillionToOne, Inc. Filed by: Atay Oguzhan

Mon, 03 Aug 2026 12:25:00 -0400

si-local-file:///var/storage/secattach/20260803/26856205.html

Form 144 BillionToOne, Inc. Filed by: Atay Oguzhan

Mon, 03 Aug 2026 12:01:00 -0400

si-local-file:///var/storage/secattach/20260803/26856089.html

Form 144 BillionToOne, Inc. Filed by: Sakakibara Shan Riku

Fri, 31 Jul 2026 11:00:00 -0400

si-local-file:///var/storage/secattach/20260731/26848570.html

Form 4 BillionToOne, Inc. For: Jul 16 Filed by: Johnson Nancy JoAnn

Mon, 20 Jul 2026 19:38:00 -0400

si-local-file:///var/storage/secattach/20260720/26790743.html

BillionToOne names oncology veteran as chief medical officer

Mon, 20 Jul 2026 09:00:37 -0400

BillionToOne, Inc. (Nasdaq: BLLN) has appointed Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, the company announced July 20. He will lead medical strategy for the company's Northstar liquid biopsy portfolio.

Dr. Dmitrovsky joins from the Frederick National Laboratory for Cancer Research, where he served as Laboratory Director and President of Leidos Biomedical Research. He previously served as Provost and Executive Vice President at the University of Texas MD Anderson Cancer Center and as Professor and Chair of Pharmacology and Toxicology at Dartmouth's Geisel School of Medicine.